Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $88 from $76 and keeps a Buy rating on the shares. The firm is positive on the recent initiation of Phase 2/3 study in Crohn’s, the company’s pipeline focused on validated targets, and Protagonist being well capitalized with at least 2028-end runway, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics: Promising Prospects and Increased Price Target Amidst Positive Study Data and Strategic Partnerships
- Protagonist Therapeutics: Promising Drug Development and Strong Clinical Progress Justify Buy Rating
- Promising Potential of Protagonist Therapeutics’ Icotrokinra Drives Buy Rating Amid Strategic Interest from Johnson & Johnson
- Clear Street sees ‘unmatched commercial promise’ for Protagonist’s icotrokinra
- Protagonist Therapeutics announces icotrokinra data in UC, plaque PsO